Bressler B. Is there an optimal sequence of biologic therapies for inflammatory bowel disease? Ther Adv Gastroenterol. 2023;16:17562848231159452.

Article  Google Scholar 

Allegretti JR, Bordeianou LG, Damas OM, Eisenstein S, Greywoode R, Minar P, Singh S, Harmon S, Lisansky E, Malone-King M, et al. Challenges in IBD research 2024: pragmatic clinical research. Inflamm Bowel Dis. 2024;30:S55–66.

Article  PubMed  Google Scholar 

Dolinger M, Torres J, Vermeire S. Crohn’s disease. Lancet. 2024;403:1177–91.

Article  PubMed  CAS  Google Scholar 

Le Berre C, Honap S, Peyrin-Biroulet L. Ulcerative colitis. Lancet. 2023;402:571–84.

Article  PubMed  Google Scholar 

Bjørlykke KH, Jahnsen J, Brynskov J, Molander P, Eberhardson M, Davidsdottir LG, Sipponen T, Hjortswang H, Goll GL, Syversen SW, et al. Therapeutic drug monitoring in inflammatory bowel disease: implementation, utilization, and barriers in clinical practice in Scandinavia. Scand J Gastroenterol. 2023;58:25–33.

Article  PubMed  Google Scholar 

Bendtzen K, Ainsworth M, Steenholdt C, Thomsen OO, Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol. 2009;44:774–81.

Article  PubMed  CAS  Google Scholar 

Steenholdt C, Brynskov J, Thomsen OO, Munck LK, Fallingborg J, Christensen LA, Pedersen G, Kjeldsen J, Jacobsen BA, Oxholm AS, et al. Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial. Gut. 2014;63:919–27.

Article  PubMed  Google Scholar 

Yanai H, Lichtenstein L, Assa A, Mazor Y, Weiss B, Levine A, Ron Y, Kopylov U, Bujanover Y, Rosenbach Y, et al. Levels of drug and antidrug antibodies are associated with outcome of interventions after loss of response to infliximab or adalimumab. Clin Gastroenterol Hepatol. 2015;13:522–30.

Article  PubMed  CAS  Google Scholar 

Roblin X, Rinaudo M, Del TE, Phelip JM, Genin C, Peyrin-Biroulet L, Paul S. Development of an algorithm incorporating pharmacokinetics of adalimumab in inflammatory bowel diseases. Am J Gastroenterol. 2014;109:1250–6.

Article  PubMed  CAS  Google Scholar 

Soendergaard C, Seidelin JB, Steenholdt C, Nielsen OH. Putative biomarkers of vedolizumab resistance and underlying inflammatory pathways involved in IBD. BMJ Open Gastroenterol. 2018;5: e000208.

Article  PubMed  PubMed Central  Google Scholar 

Christensen KR, Steenholdt C, Buhl S, Brynskov J, Ainsworth MA. A systematic monitoring approach to biologic therapies in inflammatory bowel disease: patients’ and physicians’ preferences and adherence. Scand J Gastroenterol. 2022;57:274–81.

Article  PubMed  CAS  Google Scholar 

Steenholdt C, Frederiksen MT, Bendtzen K, Ainsworth MA, Thomsen OO, Brynskov J. Time course and clinical implications of development of antibodies against adalimumab in patients with inflammatory bowel disease. J Clin Gastroenterol. 2016;50:483–9.

Article  PubMed  CAS  Google Scholar 

Steenholdt C, Lorentsen RD, Petersen PN, Widigson ES, Kloft C, Klaasen RA, Brynskov J. Therapeutic drug monitoring of vedolizumab therapy in inflammatory bowel disease. J Gastroenterol Hepatol. 2024;39:1088–98.

Article  PubMed  CAS  Google Scholar 

Feuerstein JD, Nguyen GC, Kupfer SS, Falck-Ytter Y, Singh S. American gastroenterological association institute guideline on therapeutic drug monitoring in inflammatory bowel disease. Gastroenterology. 2017;153:827–34.

Article  PubMed  Google Scholar 

Ungar B, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S. Optimizing anti-TNF-alpha therapy: serum levels of infliximab and adalimumab are associated with mucosal healing in patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2016;14:550–7.

Article  PubMed  CAS  Google Scholar 

Adedokun OJ, Xu Z, Marano CW, Strauss R, Zhang H, Johanns J, Zhou H, Davis HM, Reinisch W, Feagan BG, et al. Pharmacokinetics and exposure-response relationship of golimumab in patients with moderately-to-severely active ulcerative colitis: results from phase 2/3 PURSUIT induction and maintenance studies. J Crohns Colitis. 2017;11:35–46.

Article  PubMed  Google Scholar 

Alsoud D, Vermeire S, Verstockt B. Monitoring vedolizumab and ustekinumab drug levels in patients with inflammatory bowel disease: hype or hope? Curr Opin Pharmacol. 2020;55:17–30.

Article  PubMed  CAS  Google Scholar 

Papamichael K, Cheifetz AS, Melmed GY, Irving PM, Vande Casteele N, Kozuch PL, Raffals LE, Baidoo L, Bressler B, Devlin SM, et al. Appropriate therapeutic drug monitoring of biologic agents for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2019;17:1655-1668.e1653.

Article  PubMed  PubMed Central  CAS  Google Scholar 

Vande Casteele N, Herfarth H, Katz J, Falck-Ytter Y, Singh S. American gastroenterological association institute technical review on the role of therapeutic drug monitoring in the management of inflammatory bowel diseases. Gastroenterology. 2017;153:835-857.e836.

Article  PubMed  Google Scholar 

Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn’s disease—a systematic review with meta-analysis. Dig Liver Dis. 2022;54:1168–78.

Article  PubMed  CAS  Google Scholar 

Sparrow MP, Papamichael K, Ward MG, Riviere P, Laharie D, Paul S, Roblin X. Therapeutic drug monitoring of biologics during induction to prevent primary non-response. J Crohns Colitis. 2020;14:542–56.

Article  PubMed  Google Scholar 

Buhl S, Steenholdt C, Rasmussen M, Borghede MK, Brynskov J, Thomsen O, Ainsworth MA. Outcomes after primary infliximab treatment failure in inflammatory bowel disease. Inflamm Bowel Dis. 2017;23:1210–7.

Article  PubMed  Google Scholar 

Lallemand C, Kavrochorianou N, Steenholdt C, Bendtzen K, Ainsworth MA, Meritet JF, Blanchard B, Lebon P, Taylor P, Charles P, et al. Reporter gene assay for the quantification of the activity and neutralizing antibody response to TNFalpha antagonists. J Immunol Methods. 2011;373:229–39.

Article  PubMed  CAS  Google Scholar 

Steenholdt C, Ainsworth MA, Tovey M, Klausen TW, Thomsen OO, Brynskov J, Bendtzen K. Comparison of techniques for monitoring infliximab and antibodies against infliximab in Crohn’s disease. Ther Drug Monit. 2013;35:530–8.

Article  PubMed  CAS  Google Scholar 

Dorn-Rasmussen M, Buhl S, Brynskov J, Bay JT, Bolstad N, Klausen TW, Warren DJ, Ainsworth MA, Steenholdt C. Drug levels associated with optimal discrimination between remission and nonremission and comparison of antibody assays during first year of stable infliximab maintenance therapy in inflammatory bowel disease. Ther Drug Monit. 2022;44:290–300.

Article  PubMed  CAS  Google Scholar 

Steenholdt C, Bendtzen K, Brynskov J, Ainsworth MA. Optimizing treatment with TNF inhibitors in inflammatory bowel disease by monitoring drug levels and antidrug antibodies. Inflamm Bowel Dis. 2016;22:1999–2015.

Article  PubMed  Google Scholar 

Rodríguez-Alcolado L, Grueso-Navarro E, Arias Á, Lucendo AJ, Laserna-Mendieta EJ. Impact of HLA-DQA1∗05 genotype in immunogenicity and failure to treatment with tumor necrosis factor-alpha antagonists in inflammatory bowel disease: a systematic review and meta-analysis. J Crohns Colitis. 2024;18:1034–52.

Article  PubMed  Google Scholar